2020
The emergence of human Powassan virus infection in North America
Campbell O, Krause PJ. The emergence of human Powassan virus infection in North America. Ticks And Tick-borne Diseases 2020, 11: 101540. PMID: 32993949, DOI: 10.1016/j.ttbdis.2020.101540.Peer-Reviewed Original ResearchConceptsPowassan virusPOWV infectionSymptomatic casesLong-term neurological sequelaePowassan virus infectionState health department websitesPOWV diseaseTickborne flavivirusNeurological sequelaeHealth department websitesVirus infectionDisease controlInfection prevalenceInfectionPrevalence researchUnited StatesSurveillance effortsAge distributionIncidenceOld beingSurveillance informationGreater awarenessLiterature reviewDisease incidenceMorbidity
2005
Hypersensitivity to Ticks and Lyme Disease Risk
Burke G, Wikel SK, Spielman A, Telford SR, McKay K, Krause PJ, . Hypersensitivity to Ticks and Lyme Disease Risk. Emerging Infectious Diseases 2005, 11: 36-41. PMID: 15705320, PMCID: PMC3294369, DOI: 10.3201/eid1101.040303.Peer-Reviewed Original ResearchConceptsTick biteLyme diseaseLyme disease-endemic regionsNymphal Ixodes scapularis ticksLyme disease infectionDisease-endemic regionsCutaneous hypersensitivityIxodes scapularis ticksStudy participantsDisease riskPrior exposureDiseaseBorrelia burgdorferiFrequent exposureScapularis ticksBiteItchLyme disease riskHypersensitivityVector ticksTicksPrevious yearExposureDisease infectionResidents
2003
Increasing health burden of human babesiosis in endemic sites.
KRAUSE PJ, McKay K, Gadbaw J, Christianson D, Closter L, Lepore T, TELFORD SR, Sikand V, Ryan R, Persing D, RADOLF JD, Spielman A, _ _. Increasing health burden of human babesiosis in endemic sites. American Journal Of Tropical Medicine And Hygiene 2003, 68: 431-6. PMID: 12875292, DOI: 10.4269/ajtmh.2003.68.431.Peer-Reviewed Original ResearchConceptsYears of ageEndemic sitesCommunity-based serosurveysClinical spectrumHealth burdenPeople 20Borrelial infectionHuman infectionsBabesial infectionMore older adultsBabesia microtiBabesial antigensOlder adultsHuman babesiosisYoung adultsInfectionBorrelia burgdorferiIncidenceThree-fourthsAdultsAgePrudence IslandSeroprevalenceSerosurveyHospital
2001
Safety and Immunogenicity of a Recombinant Borrelia burgdorferi Outer Surface Protein A Vaccine Against Lyme Disease in Healthy Children and Adolescents: A Randomized Controlled Trial
Sikand V, Halsey N, Krause P, Sood S, Geller R, Van Hoecke C, Buscarino C, Parenti D. Safety and Immunogenicity of a Recombinant Borrelia burgdorferi Outer Surface Protein A Vaccine Against Lyme Disease in Healthy Children and Adolescents: A Randomized Controlled Trial. Pediatrics 2001, 108: 123-128. PMID: 11433064, DOI: 10.1542/peds.108.1.123.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntigens, SurfaceArthralgiaBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferi GroupChildChild, PreschoolEdemaErythemaExanthemaFatigueFemaleFeverHeadacheHumansImmunoglobulin GIncidenceInjectionsLipoproteinsLyme DiseaseLyme Disease VaccinesMalePainSeverity of Illness IndexTime FactorsUnited StatesConceptsLocal injection site reactionsInjection site reactionsYears of ageMonth 13LD vaccineVaccine recipientsSite reactionsHealthy childrenEfficacy studiesChildren 4Placebo-controlled clinical trialUnsolicited adverse eventsFlu-like symptomsLyme disease vaccineHigher immune responseLyme endemic areasOuter Surface ProteinsAdolescents 15 yearsIgG GMTPlacebo recipientsReactogenicity dataAdverse eventsControlled TrialsMonth 6Immunogenicity data